



US PATENT GRANTED - FURTHER EXTENDS XANAMEM PROTECTION

- **United States Patent granted for use of Xanamem™ in Alzheimer's dementia and other diseases.**
- **Xanamem™'s long patent life now further extended to 2031 in the US.**
- **Comprehensive protection over Xanamem™ now received for most major markets.**

Sydney, 20 July 2016: Actinogen Medical Limited (Actinogen Medical, ASX: ACW), is pleased to announce it has received official notification to grant from the **United States Patent Office** for the most comprehensive patent for Xanamem. This patent further extends the comprehensive cover for Xanamem through to 2031.

The patent (US 9,365,564 B2) protects the use of Xanamem™ for use in Alzheimer's dementia and other related diseases associated with the inhibition of the 11-beta-hydroxysteroid dehydrogenase (11β-HSD1) enzyme. Importantly this patent cover through to 2031 comes on top of previous approvals in most other major markets, including all European countries and the UK, Australia, Japan and China. The US patent approval is particularly significant as the US represents 50% of the global Alzheimer's disease treatment market.

Xanamem™ has been specifically designed to inhibit the excess production of cortisol, the "stress hormone", in the brain. Recent global clinical research has repeatedly demonstrated that excess cortisol is associated with cognitive decline, and amyloid plaque build-up and neurotoxicity in the brain, the hallmarks of Alzheimer's disease. Inhibition of this excess cortisol is now seen as a very promising new target for treating Alzheimer's disease. Actinogen Medical recently announced the initiation of their definitive Phase II proof-of-concept efficacy trial of Xanamem in mild Alzheimer's disease.

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multi-billion-dollar market potential. The cost of Alzheimer's treatment in the US alone was estimated to be US\$250bn in 2013, with this cost estimated to increase to US\$1 trillion by 2050, outstripping the cost of treating all other diseases. Alzheimer's disease is now the second leading cause of death in Australia behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.

ACTINOGEN MEDICAL LIMITED TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW

Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 8964 7401

WEB www.actinogen.com.au

About Actinogen Medical

Actinogen Medical is focused on an innovative approach, through the inhibition of cortisol production, for treating cognitive impairment in chronic neurodegenerative and metabolic diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to be associated with cognitive impairment and the development of amyloid plaques and neural death in the brain – the hallmarks of Alzheimer’s disease. In 2016 the Company initiated XanADu, a Phase II efficacy and safety trial in mild Alzheimer’s disease.